Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
Purpose
This is a double-blind, randomized, placebo-controlled, PoC study to evaluate the efficacy, safety, and tolerability of efzofitimod in patients with SSc-ILD. The primary objective of the study is to evaluate the PoC for efficacy in a population with SSc-ILD. While improvement of ILD is the outcome of interest, the study will also evaluate changes in the skin. After initial screening (up to 4 weeks), approximately 25 eligible participants will be randomized 2:2:1 to 1 of 2 active (experimental) dose arms or placebo, administered every 4 weeks up to and including Week 20.
Condition
- Interstitial Lung Disease
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Diagnosis of SSc based on ACR/ EULAR criteria (2013) 2. Overall duration of SSc < 48 months from the first non-Raynaud symptom manifestation 3. HRCT obtained at the Screening Visit or within the 3 months prior to Screening consistent with SSc-ILD (adjudicated by a central reader) AND with pulmonary involvement > 10% 4. Clinical presentation at Screening consistent with lcSSc (up to 40% of patients) or dcSSc 5. Presence of at least: Any 1 laboratory marker for active disease OR Clinically significant decline in FVC % predicted (%pred) based on ≥ 105% relative decline over the preceding one year (two readings from the same pulmonary function laboratory) 6. MMF of ≥ 2 gm/day (or equivalent doses of other mycophenolate based compounds) for 6 months
Exclusion Criteria
- Pulmonary disease with FVC %pred ≤ 45% OR DLco %pred ≤ 30%; FEV1/FVC ratio < 0.7 2. Participants with pulmonary artery hypertension on parenteral therapy or with clinical evidence of right heart failure 3. HRCT obtained in the 3 months prior to Screening consistent with other confounding pathology. 4. Treatment with corticosteroids (> 10 mg/day of prednisone or equivalent) within 2 weeks prior to baseline 5. SSc-ILD treatments other than MMF OR MMF < 2 gm/day 6. Any previous treatment with any of the following: rituximab, intravenous immune globulin (IVIG), tocilizumab, cyclophosphamide, pirfenidone, tyrosine-kinase inhibitors (e.g., imatinib, nilotinib, dasatinib) 7. Rheumatic autoimmune disease other than SSc, Is an active, heavy smoker of tobacco/nicotine-containing products 8. History of (anti-Jo-1) anti-synthetase syndrome or Jo-1 positive at Screening
Study Design
- Phase
- Phase 2
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- Triple (Participant, Care Provider, Investigator)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental efzofitimod 450 mg |
Administered IV infusion |
|
|
Experimental efzofitimod 270 mg |
Administered IV infusion |
|
|
Placebo Comparator Placebo |
Administered IV infusion |
|
Recruiting Locations
aTyr Investigative Site
Charleston, South Carolina 29425
Charleston, South Carolina 29425
More Details
- NCT ID
- NCT05892614
- Status
- Recruiting
- Sponsor
- aTyr Pharma, Inc.